News Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Real-time Estimate Cboe BZX Other stock markets 01:11:50 2024-05-23 pm EDT			5-day change	1st Jan Change
22.11 ^USD	-0.05%		+2.04%	-2.27%

May. 17	HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating	MT
May. 10	Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Adjusts Price Target on Cassava Sciences to $131 From $124, Maintains Buy Rating	May. 17	MT
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam	May. 13	AQ
Cassava Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam	May. 10	GL
Cassava Sciences Raises More Than $125 Million From Warrant Distribution	May. 08	MT
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution	May. 08	GL
North American Morning Briefing : Stock Futures -2-	May. 06	DJ
Cassava Sciences : Warrants – Notice of Guaranteed Delivery	May. 02	PU
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ	May. 01	GL
North American Morning Briefing : Investors Brace -2-	Apr. 29	DJ
Cassava Sciences : Corporate Presentation – Second Quarter 2024	Apr. 24	PU
Cassava Sciences, Inc. - Redemption Date Announced for Warrants	Apr. 16	AQ
Redemption Date Announced for Warrants	Apr. 15	GL
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava	Mar. 29	PR
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA	Mar. 27	PR
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA	Mar. 27	PR
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam	Mar. 25	MT
Cassava Sciences : Corporate Presentation – First Quarter 2024	Mar. 25	PU
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials	Mar. 25	GL
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials	Mar. 25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cassava Sciences, Inc.

Equities

SAVA

US14817C1071

Summary

Filters